LEXX logo

Lexaria Bioscience (LEXX) Cash From Financing

Annual CFF

$10.32 M
+$8.73 M+548.88%

August 31, 2024

Summary

Performance

1-Year Change

+548.88%

3-Year Change

-23.13%

5-Year Change

+209.51%

15-Year Change

+158.17%

LEXX Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

57.45%
LEXX annual cash flow from financing activities is higher than 57.45% of companies in Healthcare sector

High & Low

All-time High

$13.42 M
LEXX annual cash flow from financing activities is currently -23.13% below its historical high of $13.42 million

3-Year Low

-$44.60 K

Earnings dates

Last Annual Earnings Report Date

Aug 31, 2024
LEXX previous annual earnings announcement was published on Aug 31, 2024

Next Annual Earnings Report Date

N/A
LEXX next annual earnings announcement has not yet been scheduled

OtherLEXXcash flowmetrics:

Annual CFI

-$188.60 K
LEXX annual cash flow from investing activities is -$188.60 thousand

Annual CFO

-$4.96 M
LEXX annual cash flow from operations is -$4.96 million

Annual FCF

-$5.15 M
LEXX annual free cash flow is -$5.15 million

Annual CAPEX

$188.60 K
LEXX annual capital expenditures is $188.60 thousand

Quarterly CFF

$4.35 M
+$4.35 M+100.00%

November 30, 2024

Summary

Performance

3-Month Change

0%

1-Year Change

0%

3-Year Change

+100%

5-Year Change

+100%

LEXX Quarterly CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

78.13%
LEXX quarterly cash flow from financing activities is higher than 78.13% of companies in Healthcare sector

High & Low

All-time High

$9.44 M
LEXX quarterly cash flow from financing activities is currently -53.94% below its historical high of $9.44 million

3-Year Low

-$121.70 K

Earnings dates

Last Quarterly Earnings Report Date

Nov 30, 2024
LEXX previous earnings announcement was published on Nov 30, 2024

Next Quarterly Earnings Report Date

Apr 9, 2025
LEXX next earnings announcement is scheduled for Apr 9, 2025

OtherLEXXcash flowmetrics:

Quarterly CFI

-$37.80 K
LEXX quarterly cash flow from investing activities is -$37.80 thousand

Quarterly CFO

-$2.73 M
LEXX quarterly cash flow from operations is -$2.73 million

Quarterly FCF

-$2.76 M
LEXX quarterly free cash flow is -$2.76 million

Quarterly CAPEX

$37.80 K
LEXX quarterly capital expenditures is $37.80 thousand

TTM CFF

$12.84 M
+$2.53 M+24.49%

November 30, 2024

Summary

Performance

3-Month Change

0%

1-Year Change

0%

3-Year Change

+38317.86%

5-Year Change

+38317.86%

LEXX TTM CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

58.11%
LEXX TTM cash flow from financing activities is higher than 58.11% of companies in Healthcare sector

High & Low

All-time High

$13.42 M
LEXX TTM cash flow from financing activities is currently -4.31% below its historical high of $13.42 million

3-Year Low

-$44.60 K

Earnings dates

Last Quarterly Earnings Report Date

Nov 30, 2024
LEXX previous earnings announcement was published on Nov 30, 2024

Next Quarterly Earnings Report Date

Apr 9, 2025
LEXX next earnings announcement is scheduled for Apr 9, 2025

OtherLEXXcash flowmetrics:

TTM CFI

-$186.40 K
LEXX TTM cash flow from investing activities is -$186.40 thousand

TTM CFO

-$6.50 M
LEXX TTM cash flow from operations is -$6.50 million

TTM FCF

-$6.69 M
LEXX TTM free cash flow is -$6.69 million

TTM CAPEX

$186.40 K
LEXX TTM capital expenditures is $186.40 thousand

Cash From Financing Formula

CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities

LEXX Cash From Financing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+548.9%0.0%0.0%
3 y3 years-23.1%+100.0%+10000.0%
5 y5 years+209.5%+100.0%+10000.0%

LEXX Cash From Financing Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-23.1%>+9999.0%-13.8%+3670.6%-4.3%>+9999.0%
5 y5-year-23.1%>+9999.0%-53.9%+3670.6%-4.3%>+9999.0%
alltimeall time-23.1%+2923.0%-53.9%+2230.1%-4.3%+3615.3%

Lexaria Bioscience Cash From Financing History

DateAnnualQuarterlyTTM
Nov 2024
-
$4.35 M(>+9900.0%)
$12.84 M(+24.5%)
Aug 2024
$10.32 M(+548.9%)
$0.00(-100.0%)
$10.32 M(+1.2%)
May 2024
-
$5.04 M(+46.1%)
$10.19 M(+48.6%)
Feb 2024
-
$3.45 M(+89.8%)
$6.86 M(+101.3%)
Nov 2023
-
$1.82 M(-1595.0%)
$3.41 M(+114.4%)
Aug 2023
$1.59 M(-3664.3%)
-$121.70 K(-107.1%)
$1.59 M(-6.5%)
May 2023
-
$1.71 M(>+9900.0%)
$1.70 M(-7690.2%)
Feb 2023
-
$0.00(0.0%)
-$22.40 K(-33.3%)
Nov 2022
-
$0.00(-100.0%)
-$33.60 K(-24.7%)
Aug 2022
-$44.60 K(-100.3%)
-$11.20 K(0.0%)
-$44.60 K(-101.1%)
May 2022
-
-$11.20 K(0.0%)
$3.97 M(-0.0%)
Feb 2022
-
-$11.20 K(+1.8%)
$3.97 M(-70.4%)
Nov 2021
-
-$11.00 K(-100.3%)
$13.42 M(-0.0%)
Aug 2021
$13.42 M(+405.6%)
$4.00 M(<-9900.0%)
$13.42 M(+43.9%)
May 2021
-
-$11.00 K(-100.1%)
$9.33 M(-17.1%)
Feb 2021
-
$9.44 M(<-9900.0%)
$11.25 M(+480.5%)
Nov 2020
-
-$8800.00(-90.1%)
$1.94 M(-27.0%)
Aug 2020
$2.65 M(-20.4%)
-$89.20 K(-104.7%)
$2.65 M(-5.3%)
May 2020
-
$1.92 M(+1493.0%)
$2.80 M(+31.6%)
Feb 2020
-
$120.30 K(-83.0%)
$2.13 M(-10.9%)
Nov 2019
-
$706.70 K(+1097.8%)
$2.39 M(-28.3%)
Aug 2019
$3.33 M(+78.5%)
$59.00 K(-95.3%)
$3.33 M(-12.3%)
May 2019
-
$1.24 M(+226.0%)
$3.80 M(+31.5%)
Feb 2019
-
$381.30 K(-76.9%)
$2.89 M(-10.6%)
Nov 2018
-
$1.65 M(+212.6%)
$3.23 M(+73.2%)
Aug 2018
$1.87 M(-53.3%)
$527.60 K(+58.9%)
$1.87 M(+29.9%)
May 2018
-
$332.00 K(-54.2%)
$1.44 M(-63.8%)
Feb 2018
-
$725.20 K(+156.8%)
$3.97 M(-3.8%)
Nov 2017
-
$282.40 K(+189.0%)
$4.13 M(+3.4%)
Aug 2017
$4.00 M(+676.9%)
$97.70 K(-96.6%)
$4.00 M(-5.3%)
May 2017
-
$2.87 M(+224.7%)
$4.22 M(+189.7%)
Feb 2017
-
$883.50 K(+507.2%)
$1.46 M(+133.5%)
Nov 2016
-
$145.50 K(-54.8%)
$623.80 K(+21.3%)
Aug 2016
$514.30 K(+37.8%)
$321.80 K(+205.0%)
$514.30 K(+160.5%)
May 2016
-
$105.50 K(+106.9%)
$197.40 K(-64.7%)
Feb 2016
-
$51.00 K(+41.7%)
$559.00 K(+10.0%)
Nov 2015
-
$36.00 K(+634.7%)
$508.00 K(+36.1%)
Aug 2015
$373.30 K
$4900.00(-99.0%)
$373.30 K(+38.5%)
May 2015
-
$467.10 K(>+9900.0%)
$269.60 K(-68.4%)
DateAnnualQuarterlyTTM
Feb 2015
-
$0.00(-100.0%)
$853.90 K(0.0%)
Nov 2014
-
-$98.70 K(-0.1%)
$853.90 K(-14.8%)
Aug 2014
$1.23 M(-436.5%)
-
-
Jul 2014
-
-$98.80 K(-109.4%)
$1.00 M(-2.1%)
Apr 2014
-
$1.05 M(+1214.3%)
$1.02 M(-965.0%)
Jan 2014
-
$80.00 K(-366.7%)
-$118.40 K(-67.6%)
Oct 2013
-$365.40 K(-227.1%)
-$30.00 K(-61.1%)
-$365.30 K(+5.0%)
Jul 2013
-
-$77.20 K(-15.4%)
-$347.80 K(+57.7%)
Apr 2013
-
-$91.20 K(-45.4%)
-$220.60 K(+177.8%)
Jan 2013
-
-$166.90 K(+1235.2%)
-$79.40 K(-127.6%)
Oct 2012
$287.50 K(-66.6%)
-$12.50 K(-125.0%)
$287.50 K(+8.3%)
Jul 2012
-
$50.00 K(0.0%)
$265.40 K(-56.6%)
Apr 2012
-
$50.00 K(-75.0%)
$611.10 K(+15.0%)
Jan 2012
-
$200.00 K(-678.0%)
$531.40 K(-38.3%)
Oct 2011
$861.00 K(+147.1%)
-$34.60 K(-108.7%)
$861.00 K(-12.6%)
Jul 2011
-
$395.70 K(-1432.3%)
$985.60 K(+67.1%)
Apr 2011
-
-$29.70 K(-105.6%)
$589.90 K(-15.1%)
Jan 2011
-
$529.60 K(+488.4%)
$694.60 K(+99.4%)
Oct 2010
$348.40 K(-539.9%)
$90.00 K(>+9900.0%)
$348.40 K(+22.3%)
Jul 2010
-
$0.00(-100.0%)
$284.80 K(-26.0%)
Apr 2010
-
$75.00 K(-59.1%)
$385.10 K(+25.0%)
Jan 2010
-
$183.40 K(+594.7%)
$308.20 K(-489.1%)
Oct 2009
-$79.20 K(-108.4%)
$26.40 K(-73.7%)
-$79.20 K(-134.3%)
Jul 2009
-
$100.30 K(-5378.9%)
$231.00 K(-39.3%)
Apr 2009
-
-$1900.00(-99.1%)
$380.80 K(+71.4%)
Jan 2009
-
-$204.00 K(-160.6%)
$222.20 K(-76.3%)
Oct 2008
$938.90 K(-14.6%)
$336.60 K(+34.6%)
$939.00 K(+43.9%)
Jul 2008
-
$250.10 K(-255.8%)
$652.40 K(-53.5%)
Apr 2008
-
-$160.50 K(-131.3%)
$1.40 M(-13.1%)
Jan 2008
-
$512.80 K(+925.6%)
$1.61 M(+46.6%)
Oct 2007
$1.10 M(-47.7%)
$50.00 K(-95.0%)
$1.10 M(-63.9%)
Jul 2007
-
$1.00 M(+1900.0%)
$3.05 M(+48.8%)
Apr 2007
-
$50.00 K(>+9900.0%)
$2.05 M(+2.5%)
Jan 2007
-
$0.00(-100.0%)
$2.00 M(-5.0%)
Oct 2006
$2.10 M(+80.7%)
$2.00 M(>+9900.0%)
$2.10 M(+1904.8%)
Jul 2006
-
$0.00(0.0%)
$105.00 K(0.0%)
Apr 2006
-
$0.00(-100.0%)
$105.00 K(0.0%)
Jan 2006
-
$105.00 K
$105.00 K
Oct 2005
$1.17 M
-
-

FAQ

  • What is Lexaria Bioscience annual cash flow from financing activities?
  • What is the all time high annual CFF for Lexaria Bioscience?
  • What is Lexaria Bioscience annual CFF year-on-year change?
  • What is Lexaria Bioscience quarterly cash flow from financing activities?
  • What is the all time high quarterly CFF for Lexaria Bioscience?
  • What is Lexaria Bioscience quarterly CFF year-on-year change?
  • What is Lexaria Bioscience TTM cash flow from financing activities?
  • What is the all time high TTM CFF for Lexaria Bioscience?
  • What is Lexaria Bioscience TTM CFF year-on-year change?

What is Lexaria Bioscience annual cash flow from financing activities?

The current annual CFF of LEXX is $10.32 M

What is the all time high annual CFF for Lexaria Bioscience?

Lexaria Bioscience all-time high annual cash flow from financing activities is $13.42 M

What is Lexaria Bioscience annual CFF year-on-year change?

Over the past year, LEXX annual cash flow from financing activities has changed by +$8.73 M (+548.88%)

What is Lexaria Bioscience quarterly cash flow from financing activities?

The current quarterly CFF of LEXX is $4.35 M

What is the all time high quarterly CFF for Lexaria Bioscience?

Lexaria Bioscience all-time high quarterly cash flow from financing activities is $9.44 M

What is Lexaria Bioscience quarterly CFF year-on-year change?

Over the past year, LEXX quarterly cash flow from financing activities has changed by $0.00 (0.00%)

What is Lexaria Bioscience TTM cash flow from financing activities?

The current TTM CFF of LEXX is $12.84 M

What is the all time high TTM CFF for Lexaria Bioscience?

Lexaria Bioscience all-time high TTM cash flow from financing activities is $13.42 M

What is Lexaria Bioscience TTM CFF year-on-year change?

Over the past year, LEXX TTM cash flow from financing activities has changed by $0.00 (0.00%)